Z-Tech

Z-Tech (Beijing) Biotech Co., Ltd. is a clinical-stage biotechnology company based in Beijing, China, focused on the research, development, and commercialization of innovative recombinant protein vaccines and therapeutic antibodies. The company utilizes its proprietary protein engineering and large-scale manufacturing platforms to address significant unmet needs in infectious disease prevention. Its lead program, ZT001, is a 9-valent recombinant HPV vaccine currently in Phase 3 clinical trials, designed to provide broad protection against cervical cancer and other HPV-related diseases. Additionally, Z-Tech is advancing ZT002, a recombinant shingles vaccine, alongside a robust pipeline targeting respiratory syncytial virus (RSV) and other viral pathogens. Supported by prominent venture capital investors, the company aims to deliver high-quality, affordable immunization solutions for both the Chinese and global markets.